search reports

World Analgesics Market - Opportunities and Forecasts, 2015 - 2022

Report Code : allied0062
Published Date : 01 March, 2016 | No of Pages: 123

  • Report Description
  • Table of Contents
  • Related Reports
Analgesics, also known as painkillers, are used to treat and reduce pain in the body. Typically, they are used when the pain is severe and becomes unbearable for the patient. Non-opioids, opioids, and compound analgesics (a combination of both opioids and non-opioids) are the major analgesic products used globally. The emergence of analgesics is mainly attributed to the increase in acute and chronic diseases, as well as the rising incidence of cancer worldwide.Opioid drugs are the strongest types of analgesics, which are derived from opium. They are chiefly used for the treatment of moderate to severe pain and are mostly available through prescription. On the other hand, non-opioid drugs are not derived from opium but include acetaminophen. They also include non-steroidal anti-inflammatory drugs (NSAIDs) and are majorly used for the treatment of mild to moderate pain. In addition, non-opioid drugs are sometimes used alongside stronger painkillers. They are mostly available over-the-counter (OTC); however, some NSAIDs, such as Celebrex, Cataflam, and Motrin, are available through prescription only.The world analgesics market is expected to achieve moderate growth in the near future, majorly because of factors such as increase in cardiovascular disease, cancer, and arthritis and growing geriatric population. Recurring pain and aches experienced by the ageing population is another factor the helps the market growth. In addition, increasing investments in R&D by the public and private sector, with key emphasis on the classes of compounds for formulating new therapeutics, are further expected to drive the market. However, factors such as uncontrolled prescription of opioids, drug abuse, and unregulated government policies are likely to restrain the growth of the market.The report segments the analgesics market on the basis of type, route of administration, and geography. On the basis of type, the market is segmented into non-opioids and opioids. According to the route of administration, it is segmented into oral, intravenous, rectal, transdermal, and topical. Based on the geography, it is categorized into North America, Europe, Asia-Pacific, andLAMEA.Companies adopt acquisition as their key development strategy in the analgesic market. A comprehensive competitive analysis and profiles of major market players, such as Bayer AG, Novartis AG, GlaxoSmithKline PLC, Pfizer Inc., Johnson & Johnson, Reckitt Benckiser (RB), Endo Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, and Sanofi, are provided in this report.KEY BENEFITS FOR STAKEHOLDERS:This report includes a detailed quantitative analysis of the current market trends and estimations from 2015 to 2022, which assists in identifying the prevailing market opportunities.Geographically, the analgesics market is analyzed based on key regions such as North America, Europe, Asia-Pacific, andLAMEA.This study evaluates the competitive landscape of the analgesics market to aid the reader in understanding the competitive environment across the geographic locations.Furthermore, key market players within this market have been profiled in this report and their strategies are analyzed thoroughly. This helps in understanding the competitive outlook on the supply side of the market.Competitive intelligence highlights the business practices followed by leading market players across various geographic regions.Porters Five Forces analysis extensively covers the perspective of buyers and suppliers, along with the competitive rivalry among companies.SWOT analysis enables to study the internal environment of the leading companies for strategy formulation.ANALGESICS MARKET KEY SEGMENTS:By TypeNon-opioidsOpioidsBy Route of AdministrationOralIntravenousRectalTransdermalTopicalBy GeographyNorth AmericaU.S.CanadaMexicoEuropeU.K.GermanySpainSwedenFranceRussiaDenmarkRest of EUAsia-PacificJapanChinaIndiaAustraliaIndonesiaRest of APACLAMEABrazilVenezuelaChileSaudi ArabiaUAEMoroccoKenyaNigeriaRest ofLAMEA
Table of ContentsCHAPTER 1 INTRODUCTION1.1 Report description1.2 Key benefits1.3 Key market segments1.4 Research methodology1.4.1 Secondary research1.4.2 Primary research1.4.3 Analyst tools and modelsCHAPTER 2 EXECUTIVE SUMMARY2.1 CXO perspective2.2 Market beyond: what to expect by 20272.2.1 Base case scenario2.2.2 Rapid growth scenario2.2.3 Diminishing growth scenarioCHAPTER 3 MARKET OVERVIEW3.1 Market definition and scope3.2 Key findings3.2.1 Top investment pockets3.2.2 Top winning strategies3.3 Porters five forces analysis3.3.1 Low bargaining power of supplier3.3.2 Moderate bargaining power of buyers3.3.3 Low threat of new entrants3.3.4 Moderate threat of substitute3.3.5 Moderate competitive rivalry3.4 Government regulations3.5 Research & Analysis3.5.1 Clinical trials of research studies conducted for analgesics market3.6 Market dynamics3.6.1 Drivers3.6.2 Restraints3.6.3 OpportunitiesCHAPTER 4 WORLD ANALGESICS MARKET, BY TYPE, 2015-20224.1 Overview4.1.1 Market size and forecast4.2 Non-opioids4.2.1 Key market trends4.2.2 Key growth factors and opportunities4.2.3 Market size and forecast4.3 Opioids4.3.1 Key market trends4.3.2 Key growth factors and opportunities4.3.3 Market size and forecastCHAPTER 5 WORLD ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2015-20225.1 Oral route5.1.1 Market size and forecast5.2 Intravenous route5.2.1 Market size and forecast5.3 Rectal route5.3.1 Market size and forecast5.4 Transdermal route5.4.1 Market size and forecast5.5 Topical route5.5.1 Market size and forecastCHAPTER 6 WORLD ANALGESICS MARKET BY GEOGRAPHY, 2015-20226.1 North America6.1.1 Key market trends6.1.2 Key growth factors and opportunities6.1.3 Market size and forecast6.1.4 United states6.1.4.1 Market size and forecast6.1.5 Canada6.1.5.1 Market size and forecast6.1.6 Mexico6.1.6.1 Market size and forecast6.2 Europe6.2.1 Key market trends6.2.2 Key growth factors and opportunities6.2.3 Market size and forecast6.2.4 United Kingdom6.2.4.1 Market size and forecast6.2.5 Germany6.2.5.1 Market size and forecast6.2.6 Spain6.2.6.1 Market size and forecast6.2.7 Sweden6.2.7.1 Market size and forecast6.2.8 France6.2.8.1 Market size and forecast6.2.9 Russia6.2.9.1 Market size and forecast6.2.10 Denmark6.2.10.1 Market size and forecast6.2.11 Rest of Europe6.2.11.1 Market size and forecast6.3 Asia Pacific6.3.1 Key market trends6.3.2 Key growth factors and opportunities6.3.3 Market size and forecast6.3.4 Japan6.3.4.1 Market size and forecast6.3.5 China6.3.5.1 Market size and forecast6.3.6 India6.3.6.1 Market size and forecast6.3.7 Australia6.3.7.1 Market size and forecast6.3.8 Indonesia6.3.8.1 Market size and forecast6.3.9 Rest of Asia-Pacific6.3.9.1 Market size and forecast6.4 LAMEA6.4.1 Key market trends6.4.2 Key growth factors and opportunities6.4.3 Market size and forecast6.4.4 Brazil6.4.4.1 Market size and forecast6.4.5 Venezuela6.4.5.1 Market size and forecast6.4.6 Chile6.4.6.1 Market size and forecast6.4.7 Saudi Arabia6.4.7.1 Market size and forecast6.4.8 United Arab Emirates (UAE) Market size and forecast6.4.9 Morocco6.4.9.1 Market size and forecast6.4.10 Kenya6.4.10.1 Market size and forecast6.4.11 Nigeria6.4.11.1 Market size and forecast6.4.12 Rest ofLAMEA6.4.12.1 Market size and forecastCHAPTER 7 COMPANY PROFILES7.1 Bayer AG7.1.1 Company overview7.1.2 Company snapshot7.1.3 Operating business segments7.1.4 Business performance7.1.5 Key Strategic moves and developments7.1.6 SWOT analysis7.2 Novartis AG7.2.1 Company overview7.2.2 Company snapshot7.2.3 Operating business segments7.2.4 Business performance7.2.5 Key strategic moves and development7.2.6 SWOT analysis7.3 GlaxoSmithKline PLC7.3.1 Company overview7.3.2 Company snapshot7.3.3 Operating business segments7.3.4 Business performance7.3.5 Key strategies move and development7.3.6 SWOT Analysis7.4 Pfizer Inc.7.4.1 Company overview7.4.2 Company snapshot7.4.3 Operating business segments7.4.4 Business performance7.4.5 Strategic moves and developments7.4.6 SWOT analysis7.5 Johnson & Johnson7.5.1 Company Overview7.5.2 Company Snapshot7.5.3 Operating business segments7.5.4 Business performance7.5.5 Key strategic moves and developments7.5.6 SWOT analysis7.6 Reckitt Benckiser (RB)7.6.1 Company overview7.6.2 Company snapshot7.6.3 Operating business segments7.6.4 Business performance7.6.5 SWOT analysis7.7 Endo Pharmaceuticals7.7.1 Company overview7.7.2 Company snapshot7.7.3 Operating business segments7.7.4 Business performance7.7.5 Key strategic moves and developments7.7.6 SWOT analysis7.8 Bristol-Myers Squibb7.8.1 Company overview7.8.2 Company snapshot7.8.3 Business performance7.8.4 Key strategic moves and developments7.8.5 SWOT analysis7.9 Eli Lilly and Company7.9.1 Company overview7.9.2 Company snapshot7.9.3 Operating business segments7.9.4 Business performance7.9.5 Key strategic moves and developments7.9.6 SWOT analysis7.10 Sanofi7.10.1 Company Overview7.10.2 Company Snapshot7.10.3 Operating business segments7.10.4 Business performance7.10.5 Strategic moves and developments7.10.6 SWOT analysisList of FiguresFIG. 1 TOP IMPACTING FACTORS, BASE CASE SCENARIO (2022-2027)FIG. 2 TOP IMPACTING FACTORS, RAPID GROWTH SCENARIO (2022-2027)FIG. 3 TOP IMPACTING FACTORS, DIMINISHING GROWTH SCENARIO (2022-2027)FIG. 4 TOP INVESTMENT POCKETS OF ANALGESICS MARKET BY ROUTE OF ADMINISTRATION, 2015-2022FIG. 5 TOP WINNING STRATEGIESFIG. 6 TOP FACTORS IMPACTING WORLD ANALGESICS MARKET, 2015-2022FIG. 7 DRUG POISONING DEATHS INVOLVING OPIOID ANALGESICSFIG. 8 LEADING INTERNAL ANALGESIC TABLET BRANDS, 2015, BASED ON SALES ($MILLION)FIG. 9 UNITED STATES ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 10 CANADA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 11 MEXICO ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 12 UNITED KINGDOM ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 13 GERMANY KINGDOM ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 14 SPAIN KINGDOM ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 15 SWEDEN ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 16 FRANCE ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 17 RUSSIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 18 DENMARK ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 19 REST OF EUROPE ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 20 JAPAN ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 21 CHINA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 22 INDIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 23 AUSTRALIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 24 INDONESIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 25 REST OF ASIA-PACIFIC ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 26 BRAZIL ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 27 VENEZUELA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 28 CHILE ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 29 SAUDI ARABIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 30 UAE ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 31 MOROCCO ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 32 KENYA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 33 NIGERIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 34 LAMEA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)FIG. 35 REVENUE GENERATED BY BAYER AG (2012-2014)FIG. 36 BAYER AG, %REVENUE, BY BUSINESS SEGMENTS, (2014)FIG. 37 BAYER AG, % REVENUE, BY GEOGRAPHY (2014)FIG. 38 SWOT ANALYSIS OF BAYER AGFIG. 39 REVENUE GENERATED BY NOVARTIS AG (2012-2014)FIG. 40 NOVARTIS AG, % REVENUE BY BUSINESS SEGMENTS (2014)FIG. 41 NOVARTIS AG. % REVENUE BY GEOGRAPHY (2014)FIG. 42 SWOT ANALYSIS OF NOVARTIS AGFIG. 43 REVENUE GENERATED BY GLAXOSMITHKLINE PLC (2012-2014)FIG. 44 GLAXOSMITHKLINE PLC, % REVENUE BY BUSINESS SEGMENTS (2014)FIG. 45 GLAXOSMITHKLINE PLC, % REVENUE BY GEOGRAPHY (2014)FIG. 46 SWOT ANALYSIS OF GLAXOSMITHKLINE PLCFIG. 47 REVENUE GENERATED BY PFIZER INC. (2012-2014)FIG. 48 PFIZER INC., %REVENUE, BY BUSINESS SEGMENTS, (2014)FIG. 49 PFIZER INC., % REVENUE, BY GEOGRAPHY (2014)FIG. 50 SWOT ANALYSIS OF PFIZER INC.FIG. 51 REVENUE GENERATED BY JOHNSON & JOHNSON (2012-2014)FIG. 52 JOHNSON & JOHNSON, %REVENUE, BY BUSINESS SEGMENTS, (2014)FIG. 53 JOHNSON & JOHNSON, % REVENUE, BY GEOGRAPHY (2014)FIG. 54 SWOT ANALYSIS OF JOHNSON &JOHSNONFIG. 55 REVENUE GENERATED BY RECKITT BENCKISER (2012-2014)FIG. 56 RECKITT BENCKISER, % REVENUE, BY BUSINESS SEGMENTS, (2014)FIG. 57 RECKITT BENCKISER, % REVENUE, BY GEOGRAPHY (2014)FIG. 58 SWOT ANALYSIS OF RECKITT BENCKISERFIG. 59 REVENUE GENERATED BY ENDO PHARMACEUTICALS (2012-2014)FIG. 60 ENDO PHARMACEUTICALS, % REVENUE, BY BUSINESS SEGMENTS, (2014)FIG. 61 SWOT ANALYSIS OF ENDO PHARMACEUTICALSFIG. 62 REVENUE GENERATED BY BRISTOL-MYERS SQUIBB (2012-2014)FIG. 63 BRISTOL-MYERS SQUIBB, % REVENUE, BY GEOGRAPHY (2014)FIG. 64 SWOT ANALYSIS OF BRISTOL-MYERS SQUIBBFIG. 65 REVENUE GENERATED BY ELI LILY (2012-2014)FIG. 66 ELI LILY, %REVENUE, BY BUSINESS SEGMENTS, (2014)FIG. 67 ELI LILY, % REVENUE, BY GEOGRAPHY (2014)FIG. 68 SWOT ANALYSIS OF ELI LILYFIG. 69 REVENUE GENERATED BY SANOFI (2012-2014)FIG. 70 SANOFI, %REVENUE, BY BUSINESS SEGMENTS, (2014)FIG. 71 SANOFI, %REVENUE, BY GEOGRAPHY (2014)FIG. 72 SWOT ANALYSIS OF SANOFIList of TableTABLE 1 WORLD ANALGESICS MARKETBASE CASE SCENARIO MARKET, BY GEOGRAPHY, 2022 2027 ($MILLION)TABLE 2 WORLD ANALGESICS MARKET RAPID GROWTH SCENARIO MARKET, BY GEOGRAPHY, 2022 2027 ($MILLION)TABLE 3 WORLD ANALGESICS MARKET DIMINISHING GROWTH SCENARIO MARKET, BY GEOGRAPHY, 2022 2027 ($MILLION)TABLE 4 PORTERS FIVE FORCES ANALYSISTABLE 5 CLINICAL TRIALS - ANALGESICSTABLE 6 GLOBAL INCIDENCES OF DISEASESTABLE 7 WORLD ANALGESICS MARKET, BY TYPE, 2015-2022 ($MILLION)TABLE 8 WORLD NON-OPIOIDS ANALGESICS MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)TABLE 9 WORLD OPIOID ANALGESICS MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)TABLE 10 WORLD ANALGESICS MARKET BY ROUTE OF ADMINISTRATION, 2015-2022 ($MILLION)TABLE 11 WORLD ANALGESICS ORAL ROUTE MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)TABLE 12 WORLD ANALGESICS INTRAVENOUS ROUTE MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)TABLE 13 WORLD ANALGESICS RECTAL ROUTE MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)TABLE 14 WORLD ANALGESICS TRANSDERMAL ROUTE MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)TABLE 15 WORLD ANALGESICS TOPICAL ROUTE MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)TABLE 16 WORLD ANALGESICS MODE OF APPLICATION BY TYPE, 2015-2022 ($MILLION)TABLE 17 WORLD ANALGESICS MODE OF APPLICATION BY TYPE, 2015-2022 ($MILLION)TABLE 18 WORLD ANALGESICS MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)TABLE 19 NORTH AMERICA ANALGESICS MARKET, BY TYPE, 2015-2022 ($MILLION)TABLE 20 NORTH AMERICA ANALGESICS MARKET, BY COUNTRY, 2015-2022 ($MILLION)TABLE 21 EUROPE ANALGESICS MARKET, BY TYPES, 2015-2022 ($MILLION)TABLE 22 EUROPE ANALGESICS MARKET, BY COUNTRY, 2015-2022 ($MILLION)TABLE 23 ASIA PACIFIC ANALGESIC MARKET, BY TYPES, 2015-2022 ($MILLION)TABLE 24 ASIA PACIFIC ANALGESIC MARKET, BY COUNTRY, 2015-2022 ($MILLION)TABLE 25 LAMEA ANALGESICS MARKET, BY TYPES, 2015-2022 ($MILLION)TABLE 26 LAMEA ANALGESICS MARKET, BY COUNTRY, 2015-2022 ($MILLION)TABLE 27 COMPANY SNAPSHOT OF BAYER AGTABLE 28 BAYER AG OPERATING SEGMENTSTABLE 29 COMPANY SNAPSHOT OF NOVARTIS AGTABLE 30 NOVARTIS AG OPERATINGSEGEMENTSTABLE 31 GLAXOSMITHKLINE PLC SNAPSHOTTABLE 32 GLAXOSMITHKLINE PLC OPERATINGSEGEMENTSTABLE 33 COMPANY SNAPSHOT OF PFIZER INC.TABLE 34 PFIZER INC. OPERATING SEGMENTSTABLE 35 COMPANY SNAPSHOT OF JOHNSON &JOHSNONTABLE 36 JOHNSON &JOHSNON OPERATING SEGMENTSTABLE 37 COMPANY SNAPSHOT OF RBTABLE 38 RECKITT BENCKISER OPERATING SEGMENTSTABLE 39 COMPANY SNAPSHOT OF ENDO PHARMACEUTICALSTABLE 40 ENDO PHARMACEUTICALS OPERATING SEGMENTSTABLE 41 COMPANY SNAPSHOT OF BRISTOL-MYERS SQUIBBTABLE 42 COMPANY SNAPSHOT OF ELI LILY AND COMPANYTABLE 43 ELI LILY OPERATING SEGMENTSTABLE 44 COMPANY SNAPSHOT OF SANOFITABLE 45 SANOFI OPERATING SEGMENTS
Please select License
Single User Price:$ 4740
Site License Price:$ 5910
Enterprise Price:$ 8250